EUVIMEDEUVIMED entdecken
Crossref

MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer

Wang Liu, Lily He, Cuncong Zhong, Yuzhuo Wang, Da Zhang, Moben Mirza, Benyi Li

Drug Resistance Updates · 2026

DOI: 10.1016/j.drup.2026.101463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Wang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Urology, The University of Kansas Medical Center, Kansas City, KS 66160, USA. Hauptthemen laut MEDLINE: Kruppel-Like Transcription Factors, Glyceraldehyde-3-Phosphate Dehydrogenases, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug resistance to the androgen receptor (AR) antagonist is a critical obstacle in the clinic for advanced prostate cancers. Especially, AR antagonist treatment-induced neuroendocrine progression represents a lethal and therapy-resistant subtype. Although transcriptional and epigenetic lineage plasticity have been extensively implicated in treatment-induced neuroendocrine progression, the contribution of metabolic adaptation remains incompletely understood. Here, we identified a previously unrecognized metabolic reprogramming mechanism induced by AR antagonists in castration-resistant prostate cancer (CRPC) models. AR antagonist treatment markedly enhanced glycolytic activity and induced glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. Genetic depletion of GAPDH suppressed AR antagonist-induced glycolytic activation, altered transcriptomic and metabolic programs, reduced neuroendocrine-associated marker expression, and inhibited xenograft tumor growth. Mechanistically, GAPDH promoter pulldown coupled with mass spectrometry, siRNA screening, and chromatin immunoprecipitation assays identified myeloid zinc finger-1 (MZF1) as a key transcription factor for Enzalutamide-induced GAPDH gene expression. Pharmacological inhibition of GAPDH using koningic acid (KA) or penta-O-galloyl-β-D-glucopyranose (PGG) significantly suppressed tumor growth and attenuated neuroendocrine-associated molecular programs in CRPC cell-derived xenograft and patient-derived t-NEPC xenograft models. Collectively, our findings identify an AR antagonist-induced MZF1-GAPDH signaling axis that promotes glycolytic activation and neuroendocrine-associated metabolic adaptation during treatment resistance. These results support targeting GAPDH-dependent metabolic reprogramming as a potential therapeutic strategy for treatment-resistant prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kruppel-Like Transcription FactorsGlyceraldehyde-3-Phosphate DehydrogenasesProstatic Neoplasms, Castration-ResistantMaleHumansGlycolysisAnimalsMetabolic ReprogrammingGene Expression Regulation, NeoplasticMiceCell Line, TumorDisease ProgressionAndrogen Receptor AntagonistsXenograft Model Antitumor AssaysReceptors, AndrogenProstatic NeoplasmsGlyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)

Stichwörter der Autor:innen

EnzalutamideGAPDHGlycolysisMZF1Neuroendocrine progressionProstate cancer

Substanzen

Kruppel-Like Transcription FactorsGlyceraldehyde-3-Phosphate DehydrogenasesMZF1 protein, humanAndrogen Receptor AntagonistsGAPDH protein, humanReceptors, AndrogenGlyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)

Autor:innen und Institutionen

  • Departments of Urology, The University of Kansas Medical Center, Kansas City, KS 66160, USA.
  • Departments of Pathology & Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA.
  • Department of Electrical Engineering & Computer Science, The University of Kansas School of Engineering, Lawrence, KS 66045, USA.
  • Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver V5Z 1M9, Canada.
  • Departments of Urology, The University of Kansas Medical Center, Kansas City, KS 66160, USA; Departments of Pathology & Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA. Electroni…

Zitieren

APA

Liu, W., He, L., Zhong, C., Wang, Y., Zhang, D., Mirza, M., & Li, B. (2026). MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2026.101463

Vancouver

Liu W, He L, Zhong C, Wang Y, Zhang D, Mirza M, et al. MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2026.101463

BibTeX
@article{Liu2026,
  author = {Liu, Wang and He, Lily and Zhong, Cuncong and Wang, Yuzhuo and Zhang, Da and Mirza, Moben and Li, Benyi},
  title = {MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer},
  journal = {Drug Resistance Updates},
  year = {2026},
  doi = {10.1016/j.drup.2026.101463}
}
Kostenlos starten →